Hypoxia and drug resistance

Cancer and Metastasis Reviews

Volumn 13, Issue 2, 1994, Pages 139-168

  Teicher, Beverly A ^a  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

Author keywords

drug resistance; hypoxia; hypoxic cell selective agents; physiological drug resistance; radiation sensitizers; tumor oxygenation

Indexed keywords

1 AZIRIDINO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETANIDAZOLE; ETOPOSIDE; MELPHALAN; MITOMYCIN C; PORFIROMYCIN; TIRAPAZAMINE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARDIOTOXICITY; CELL HYPOXIA; CELL METABOLISM; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG RESISTANCE; GENETIC STABILITY; HYPOXIC CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; SOLID TUMOR; TISSUE OXYGENATION;

ANIMAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL HYPOXIA; DRUG RESISTANCE; HUMAN; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; OXYGEN; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028307739     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/BF00689633     Document Type: Article

References (241)

1. Angiogenesis and blood flow
2. Oxygenation of solid tumors
3. Therapeutic attack of hypoxic cells of solid tumors: presidential address
4. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review
5. The hypoxic tumor cell: a target for selective cancer chemotherapy
6. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells
7. Determinants of tumor blood flow: a review
8. Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure
9. Heterogeneous oxygen partial pressure and pH distribution C3H mouse mammary adenocarcinoma
10. Blood flow, oxygen consumption and tissue oxygenation of human breast cancer xenografts in nude rats
11. Increase in pO2 and radiosensitivity of tumors by Fluosol-DA (20%) and carbogen
12. Increase in tumor pO2 by perfluorochemicals and carbogen
13. In vivo utilization of oxygen and glucose by neoplastic tissue
14. Hypoxic fractions of solid tumors
15. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay
16. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of therapy
17. Effect of oxygen on the cytotoxicity and antitumor activity of etoposide
18. Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity
19. Effects of various oxygenation conditions on the enhancement by Fluosol-DA of melphalan antitumor activity
20. Effect of various oxygenation conditions and Fluosol-DA on cancer chemotherapeutic agents
21. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N′,N″-triethylenethiophosphoramide
22. Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro
23. Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies
24. Effect of hypoxia and acidosis on the cytotoxicity of four platinum complexes at normal and hyperthermic temperatures
25. Interaction of hyperthermia and radiation: hypoxia and acidosis in vitro, tumor subpopulations in vivo
26. Adaptation to low pH modifies thermal and thermochemical responses of mammalian cells
27. In vitro systems for evaluation of combination chemotherapy
28. The effect of prolonged hypoxia on growth and viability of Chinese hamster ovary cells
29. Characterization of radiation resistant hypoxic cell subpopulations in KHT sarcomas (ii) Cell sorting
30. Survival responses of dividing and nondividing mammalian cells after treatment with hydroxyurea, arabinosylcytosine, or Adriamycin
31. Response of mammalian cells following treatment with bleomycin and 1,3-bis(2-chloroethyl)-1-nitrosourea during plateau phase
32. Cell proliferation kinetics and drug sensitivity of exponential and stationary populations of cultured L1210 cells
33. Comparative chemosensitivity of exponential versus plateau-phase cells in both in vitro and in vivo model systems
34. Hypoxia and neoplastic tissue
35. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in FSaIIC murine fibrosarcoma
36. A multicomponent x-ray survival curve for mouse lymphosarcoma cells irradiated in vivo
37. The phenomenon of reoxygenation and its implications for fractionated radiotherapy
38. Cellular radiosensitivity and tumor radiation response in the EMT-6 tumor cell system
39. Response of anoxic C3H mouse mammary carcinoma isotransplants (1–25 mm3) to × irradiation
40. Hyperbaric oxygen and radiobiology of the C3H mouse mammary carcinoma
41. Pre-therapeutic experiments with the fast neutron beam from the medical research council cyclotron
42. Hyperbaric oxygen and radiotherapy of a fibrosarcoma and of squamous-cell carcinoma of C3H mice
43. The gross response of an experimental tumour to single doses of x-ray
44. Tumour cure rate and cell survival of a transplantable rat rhabdomyosarcoma following x-irradiation
45. Experimental radiotherapy of a rat rhabdomyosarcoma with 15 MeV neutrons and 300 kV x-rays. I. Effects of single exposure
46. Oxygenation status of a transplantable tumor during fractionated radiation therapy
47. Tumor reoxygenation during fractionated radiotherapy: studies with a transplantable mouse osteosarcoma
48. An estimation of changes in the proportions and absolute numbers of hypoxic cells after irradiation of transplanted C3H mouse mammary tumours
49. Time-dose relationships for the cure of an experimental rat tumor with fractionated radiation
50. Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone
51. Lack of complications in long-term survivors after treatment with fluosol® and oxygen as an adjuvant to radiation therapy for high-grade brain tumors
52. Changes in the oxygenation of head and neck tumors during carbogen breathing
53. Perfluorochemical emulsions: Oxygen breathing in radiation sensitization and chemotherapy modulation
54. Use of fluosol-DA/oxygen breathing with radiation therapy and chemotherapy/radiation combinations
55. Radiosensitivity, blood perfusion and tumour oxygenation after perflubron emulsion injection
56. Pentobarbital anesthesia and the response of tumor and normal tissue in the C3Hf/sed mouse to radiation
57. Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial
58. Definitive evidence for hypoxic cells influencing cure in chemotherapy
59. Perfluorochemical emulsion can increase tumor radiosensitivity
60. Optimization of perfluorochemical levels with radiation therapy in mice
61. Oxygen-carrying perfluorochemical emulsion as an adjuvant to radiation therapy in mice
62. Effect of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion, Fluosol-DA
63. Influence of scheduling, dose, and volume of administration of a perfluorochemical emulsion on tumor response to radiation therapy
64. Effect of Fluosol-DA® on the response of intracranial 9L tumors to x-rays and BCNU
65. Effects of Fluosol-DA 20% and carbogen on the radioresponse of SCK tumors and skin of A/J mice
66. Radiosensitization of murine tumors by Fluosol-DA 20%
67. Effect of a perfluorochemical emulsion on the radiation response of BA-1112 rhabdomyosarcomas
68. Applicability of animal tumor data to cancer therapy in humans
69. Tumor sensitization by the intermittent use of perfluorochemical emulsions and carbogen breathing in fractionated radiotherapy
70. Reactions of tumors and normal tissues in mice to irradiation in the presence and absence of a perfluorochemical emulsion
71. Increased radiosensitivity of tumors by perfluorochemicals and carbogen
72. A clinical trial of Fluosol-DA® 20% in advanced squamous cell carcinoma of the head and neck
73. Phase I/II study of Fluosol-DA and 100% oxygen breathing as an adjuvant to radiation in the treatment of advanced squamous cell tumors of the head and neck
74. Fluosol and oxygen breathing as an adjuvant to radiation therapy in the treatment of locally advanced non-small cell carcinoma of the lung: results of a phase I/II study
75. A phase I–II study of the use of fluosol-da 20z as an adjuvant to radiation therapy in the treatment of primary high-grade brain tumors
76. Increases in tumor response by pentoxifylline alone or in combination with nicotinamide
77. Tumor oxygenation and radiosensitization by pentoxifylline and a perflubron emulsion/carbogen breathing
78. Exploitation of the oxygen enhancement ratio in clinical practice
79. Time-dose relationships in radiotherapy
80. Bleomycin - mode of action with particular reference to the cell cycle
81. Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM)
82. Effect of bleomycin-radiotherapy combination in management of head and neck squamous cell carcinoma
83. Adjuvant chemotherapy in head and neck cancer. An update
84. The chemistry of activated bleomycin
85. Effect of chelating agents and metal ions on the degradation of DNA by bleomycin
86. DNA damage induced by bleomycin in the presence of bibucaine is not predictive of cell growth inhibition
87. The mechanism of the bleomycin-induced cleavage of DNA
88. The production of hydroxy radical by bleomycin and iron (II)
89. Production of free radicals from phenol and tocopherol by bleomycin-iron (II)
90. Bleomycin A2: a ferrous oxide
91. Sequence specific cleavage of DNA by the antitumor antibiotics neocarzinostatin and bleomycin
92. Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage
93. Single-strand and double-strand deoxyribonucleic acid breaks produced by several bleomycin analogues
94. Inhibition of the genotoxicity of bleomycin by superoxide dismutase
95. Structural basis for the deoxyribonucleic acid affinity of bleomycin
96. Specificity of deoxyribonucleic acid cleavage by bleomycin, phleomycin, and tallysomycin
97. Effect of Fluosol-DA/O2 on the antitumor activity and pulmonary toxicity of bleomycin
98. Inhibition of topoisomerase II by VP-16-213 (etoposide), VM-26 (teniposide) and structured congeners as an explanation for in vivo DNA breakage and cytotoxicity
99. Comparison of cytotoxicity and DNA breakage activity of congeners of epipodophyllotoxin including BP-16-213 and VM-26: a quantitative structure-activity relationship
100. Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors
101. DNA topoisomerases as targets for cancer therapy
102. Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis and DNA strand size in cultures of human leukemic lymphoblasts
103. Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells
104. Interaction of VP-16-213 on the intracellular degradation of DNA in HeLa cells
105. Role of bioactivation in covalent binding of VP-16 to rat liver and HeLa cell microsomal proteins
106. DNA damage as a basis for 4′-dimethylepipodophyllotoxin-9-(4,6- O-ethylidene-β-D-glucopyranoside) (etoposide) cytotoxicity
107. Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents
108. Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro
109. Effect of Fluosol®-DA/carbogen on etoposide/alkylating agent antitumor activity
110. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo
111. The interaction of cisplatin plus etoposide with radiation ± hyperthermia
112. Anthracyclines
113. Tumor cell resistance to anthracycline: A review
114. Mode and mechanism of action
115. New developments on the mechanisms of action of antineoplastic drugs
116. Strand scission of DNA by bound Adriamycin and daunorubicin in the presence of reducing agents
117. Anthracycoine antibiotic pharmacology and metabolism
118. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation
119. A general mechanism for microsomal activation of quinone anticancer agents to free radicals
120. Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation
121. Electron spin resonance study on the mode of generation of free radicals of daunomycin, Adriamycin and carbogquone in NAD(P) H-microsome system
122. Bioactivation as a model for drug design bioreductive alkylation
123. The resistance of hypoxic mammalian cells to chemotherapeutic agents (Abstr)
124. Effects of Adriamycin and x-rays on euoxic and hypoxic EMT6 cells in vitro
125. Response of aerobic and hypoxic cells in a solid tumor to Adriamycin and cyclophosphamide and interaction of the drugs with radiation
126. Generation of free radicals and lipid peroxidation by redox cycling of Adriamycin and daunomycin
127. Spintrapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs
128. The biology of oxygen radicals
129. Effects of Fluosol®-DA and oxygen breathing on adriamycin antitumor activity and cardiac toxicity in mice
130. Survey of the effect of adding Fluosol-DA 20%/O2 to treatment with various chemotherapeutic agents
131. Effect of hypoxia and acidosis on the cytotoxicity of mitoxantrone, bisantrene and amsacrine and their platinum complexes at normal and hyperthermic temperatures
132. Taxol and Taxotere: Current Status and Future Prospects
133. Induction characteristics of oxygen-regulated proteins
134. Frequencies of independent and simultaneous selection of Chinese hamster cells for methotrexate and doxorubicin (adriamycin resistance)
135. Glucose starvation and acidosis: effect on experimental metastatic potential, DNA content and MTX resistance of murine tumour cells
136. Drug resistance in Chinese hamster ovary cells during recovery from severe hypoxia
137. Oxygen concentration regulates EGF-induced proliferation and EGF-receptor down regulation
138. c- fos expression in human skin fibroblasts by reperfusion after oxygen deficiency: a recovery change of human skin fibroblasts after oxygen deficiency stress
139. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells
140. Effects of reoxygenation of cells from hypoxic regions of solid tumors: anticancer drug sensitivity and metastatic potential
141. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance
142. The effect of hypoxia on acquired drug resistance and response to epidermal growth factor in Chinese hamster lung fibroblasts and human breast-cancer cells in vitro
143. Multiple fractions of gamma rays induced resistance to cis-dichlorodiammineplatinum (II) and methotrexate in human HeLa cells
144. Radiation induction of drug resistance in RIF-1 tumors and tumor cells
145. Enhancement of the frequency of methotrexate resistance by γ-radiation in Chinese hamster ovary and mouse 3T3 cells
146. Differential expression of collateral sensitivity or resistance to cisplatin in human bladder carcinoma cell lines pre-exposed in vitro to either x-irradiation or cisplatin
147. Molecular mechanisms of cross-linking by alkylating agents and platinum complexes
148. Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links
149. DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum (II) and phenylalanine mustard
150. Cyclophosphamide (Cytoxan): a review on relevant pharmacology and clinical uses
151. High dose therapy and bone marrow transplantation
152. The mechanism of activation of 4-hydroperoxycyclophosphamide
153. Accelerated decomposition of 4-hydroperoxycyclophosphamide by human serum albumin
154. Cyclophosphamide and related phosphoramide mustards: current status and future prospects
155. A dose-response study of resistance of leukemia L1210 to cyclophosphamide
156. Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and -resistant L1210 cells
157. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines
158. Collateral sensitivity to cross-linking agents exhibited by cultured L1210 cells resistant to oxazaphosphorines
159. Cyclophosphamide resistance developed in a human melanoma cell line
160. Ovarian reticular cell sarcoma of the mouse (M5076) made resistant to cyclophosphamide
161. Development of characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line
162. Development of drug resistance in a murine mammary tumor
163. The effect of Fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo. Cancer Chemother
164. Recent and current investigations of radiation therapy of malignant gliomas
165. Therapy of adult malignant brain tumors: What have the clinical trials taught us?
166. Radiation therapy for brain tumors
167. Chemotherapy of brain tumors: physiological and pharmacokinetic considerations
168. Principles of brain tumor chemotherapy
169. Effectiveness of the nitrosourea as a function of lipid solubility for the chemotherapy of experimental rat brain tumors
170. In vitro evaluation of in vivo brain tumor chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea
171. Effect of combined surgery and BCNU (NSU 409962) on an animal brain tumor model
172. Use of perfluorochemical emulsion to improve oxygenation in a solid tumor
173. Intermittent use of a perfluorochemical emulsion (Fluosol-DA 20%) and carbogen breathing with fractionated irradiation
174. Enhancement of tumor radiation response by the combination of a perfluorochemical emulsion and hyperbaric oxygen
175. The role of mitomycin antibiotics in the chemotherapy of solid tumors
176. pH dependence of mitomycin C-induced cross-linking activity in EMT6 tumor cells
177. Effects of glutathione and ethylxanthate on mitomycin C activation by isolated rat hepatic or EMT6 mouse mammary tumor nuclei
178. Role of NADPH: cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C
179. Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicumarol in vivo and in vitro
180. Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair-deficient mutant
181. Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo
182. Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics
183. Circular dichromism spectroscopy as a probe for the stereochemistry of aziridine cleavage reactions of mitomycin C
184. Reaction of acid-activated mitomycin C with calf thymus DNA and model guanines: elucidation of the base-catalyzed degradation of N7-alkylguanine nucleosides
185. Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells
186. Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells
187. Mitomycin C a prototype bioreductive alkylating agent: in vitro studies of metabolism and cytotoxicity
188. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay
189. Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA®/carbogen/radiation
190. Addition of mitomycin C to cis-diamminedichloroplatinum(II)/hyperthermia/radiation therapy in the FSaIIC fibrosarcoma
191. Radiation sensitization and chemopotentiation: RSU-1069, a compound more effective than misonidazole in vitro and in vivo
192. The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor
193. Misonidazole and other hypoxia markers. Metabolism and applications
194. Sensitizers and radiation dose fractionation: results and interpretations
195. The production of strand breaks in DNA in the presence of the hydroxylamine of SR-2058 (1-[N-(2-hydroxyethyl)acetamido]-2-nitroimidazole)
196. Enhancement of chemotherapy agents
197. Oxygen dependence for chemosensitization by misonidazole
198. Modification of chemotherapy by nitroimidazoles
199. DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum (II) and etanidazole with or without hyperthermia
200. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity
201. Influence of scheduling on two-drug combinations of alkylating agents in vivo
202. Combination of etanidazole with cyclophosphamide and platinum complexes
203. Etanidazole as a modulator of combined modality therapy in the rat 9L gliosarcoma
204. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma
205. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233
206. Pre- and post-irradiation radiosensitization by SR 4233
207. Structure-activity relationships for benzotriazine di- N-oxides
208. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma
209. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233)
210. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity
211. In vitro hepatotoxicity of SR 4233 (3-amino-1,2,4-benzotriazine-1,4-dioxide), a hypoxic cytotoxin and potential antitumor agent
212. The interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo
213. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors
214. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di- N-oxide hypoxic cell cytotoxin
215. Comparison between x-rays and SR 4233 for cytotoxicity and repair of potentially lethal damage in human cells
216. Aerobic radiosensitization by SR 4233 in vitro and in vivo
217. SR 4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours
218. Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma
219. RSU-1069 a 2-nitroimidazole containing an alkylating group: high efficacy as a radio- and chemosensitiser in vitro and in vivo
220. The experimental development of bioreductive drugs and their role in cancer therapy
221. Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU-10690
222. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU-1069
223. Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU-1069 in mice
224. High uptake of RSU-1069 and it analogues into melanotic melanomas
225. Effect of oxygenation, pH and hyperthermia on RSU-1069 in vitro and in vivo with radiation in the FSaIIC murine fibrosarcoma
226. A new concentrated perfluorochemical emulsion and carbogen breathing as a adjuvant to treatment with antitumor alkylating agents
227. Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents